Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting : Episode 7
Treatment Considerations With Regorafenib in Colorectal Cancer
Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.
EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting
EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment
EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment
EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab
EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC
EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer
Now Viewing
EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer
EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma
EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC
EP: 11.Toxicity Considerations and Treatment Decisions in CRC
EP: 12.Multidisciplinary Care for Patients with CRC
EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer
Related Videos
Related Content
